Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine

ÖZEN S., BİLGİNER Y., Ayaz N., Calguneri M.

JOURNAL OF RHEUMATOLOGY, vol.38, no.3, pp.516-518, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 3
  • Publication Date: 2011
  • Doi Number: 10.3899/jrheum.100718
  • Journal Name: JOURNAL OF RHEUMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.516-518
  • Keywords: FAMILIAL MEDITERRANEAN FEV, ANAKINRA, RESISTANT, ETANERCEPT, ANAKINRA, CHILDREN, PROTEIN, PYRIN
  • Istanbul University Affiliated: No

Abstract

Objective. Familial Mediterranean fever (FMF) is a recessively inherited autoinflammatory disorder characterized by recurrent attacks of fever and serositis. Although colchicine is the standard therapy for preventing attacks and suppressing inflammation, 5%-10% of compliant patients are colchicine-resistant. We report the effect of anti-tumor necrosis factor therapy (etanercept) and anti-interleukin 1 (IL-1) treatment (anakinra) in 6 cases resistant to colchicine therapy.